世界の心臓マーカー検査市場(~2025年):製品別(試薬、機器)、構成要素別(トロポニンI&T、CK-MB、ミオグロビン、BNP、hsCRP)、疾患別(心筋梗塞、うっ血性心不全、アテローム性動脈硬化症)、エンドユーザー別(研究所、PoC、学術)

◆英語タイトル:Cardiac Marker Testing Market by Product (Reagent, Instrument), Component (Troponin I & T, CK-MB, Myoglobin, BNP, hsCRP), Disease (Myocardial Infarction, Congestive Heart Failure, Atheresclerosis), Enduser (Lab, PoC, Academia) - Global Forecasts to 2025
◆商品コード:MD-4673
◆発行会社(リサーチ会社):MarketsandMarkets
◆発行日:2021年1月19日
◆ページ数:163
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥564,300見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥758,100見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥929,100見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarkets社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
MarketsandMarkets社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

マーケッツアンドマーケッツ社は世界の心臓マーカー検査市場規模が2020年36億ドルから2025年55億ドルまで、年平均8.9%成長すると予測しています。本調査レポートでは、心臓マーカー検査の世界市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、製品別(試薬・キット、機器)分析、バイオマーカータイプ別(トロポニンI・T、CK-MB、BNP・NT-PROBNP、ミオグロビン、HSCRP、その他)分析、疾患別(心筋梗塞、うっ血性心不全、急性冠症候群、アテローム性動脈硬化症、虚血)分析、エンドユーザー別(実験試験施設、学術機関、PoC検査施設)分析、地域別分析、競争状況、企業評価マトリックス/企業情報を掲載しています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・心臓マーカー検査の世界市場規模:製品別(試薬・キット、機器)
・心臓マーカー検査の世界市場規模:バイオマーカータイプ別(トロポニンI・T、CK-MB、BNP・NT-PROBNP、ミオグロビン、HSCRP、その他)
・心臓マーカー検査の世界市場規模:疾患別(心筋梗塞、うっ血性心不全、急性冠症候群、アテローム性動脈硬化症、虚血)
・心臓マーカー検査の世界市場規模:エンドユーザー別(実験試験施設、学術機関、PoC検査施設)
・心臓マーカー検査の世界市場規模:地域別
・競争状況
・企業評価マトリックス/企業情報
【レポートの概要】

“The global cardiac marker testing market size is projected to reach USD 5.5 billion by 2025 from USD 3.6 billion in 2020, at a CAGR of 8.9%. ”
The growth in the cardiac marker testing market is majorly driven by the growing incidence of cardiovascular diseases, rapidly increasing geriatric population, growing funding from public and private organizations for research on cardiac biomarkers, and ongoing clinical trials for the identification of novel cardiac biomarkers. However, factors such as technical problems related to sample collection and storage and issues related to regulatory and reimbursement systems are expected to restrain market growth to a certain extent.

The cardiac marker testing market is also faced a period of short-term negative growth, which can be attributed to factors such as a greater than 50% drop in the number of patients with cardiovascular conditions and those diagnosed with myocardial infarction. All areas of cardiology service provision sustained significant reductions, which included outpatient clinics, investigations, procedures, and cardiology community services such as cardiac rehabilitation.

“Wide use of reagents and kits in all basic diagnostic activities in laboratories, academic institutes, and POC settings is expected to result in the segment occupying the majority of the cardiac marker testing market share”
Growing number of cardiac marker testing procedures, accessibility to a wide range of cardiac biomarker reagents and kits, and the growing demand for reliable, specific, and faster detection of cardiovascular diseases at an early stage are the key growth factors for this segment.

“Troponin I and T estimated to be the fastest-growing market “
Troponin I and T is estimated to be the fastest-growing segment in the cardiac marker testing market. The large share of this segment can be attributed high sensitivity and specificity, long elevation times, and rapid prediction of outcome or mortality.

“The Asia Pacific market to grow at the highest CAGR during the forecast period”
The cardiac marker testing market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific is estimated to be the fastest-growing market for cardiac marker testing during the forecast period. The Asia Pacific market is driven due increased healthcare spending by a larger population base, healthcare infrastructure modernization, and the rising penetration of cutting-edge clinical laboratory technologies (especially in rural areas) in Asia Pacific countries.

Breakdown of supply-side primary interviews:
• By Company Type: Tier 1: 48%, Tier 2: 36%, and Tier 3: 16%
• By Designation: C-level: 10%, D-level: 14%, and Others: 76%
• By Region: North America: 40%, Europe: 32%, APAC: 20%, Latin America: 5%, and the Middle East & Africa: 3%

The major players operating in the cardiac marker testing market are Roche Diagnostics Ltd. (Switzerland), Abbott Laboratories (US), Siemens Healthineers AG (Germany), Danaher Corporation (US), bioMérieux SA (France), LSI Medience Corporation (Japan), Ortho Clinical Diagnostics (US), Randox laboratories Ltd. (UK), Guangzhou Wondfo Biotech Co., Ltd (China), DiaSorin S.p.A. (Italy), Becton, Dickinson and Company (US), Bio-Rad Laboratories, Inc. (US), PerkinElmer Inc. (US), Thermo Fisher Scientific Inc. (US), and Tosoh Corporation (Japan)

Research Coverage
This report studies the cardiac marker testing market based on the product, biomarker type, disease, end user, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).

Key Benefits of Buying the Report
This report focuses on various levels of analysis—industry trends, market share of top players, and company profiles, which together form basic views and analyze the competitive landscape, emerging segments of the cardiac marker testing market, and high-growth regions and their drivers, restraints, opportunities, and challenges. The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the market and garner greater market shares.

【レポートの目次】

1 INTRODUCTION 23
1.1 OBJECTIVES OF THE STUDY 23
1.2 MARKET DEFINITION 23
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY 23
1.3 MARKET SCOPE 24
1.3.1 MARKETS COVERED 24
1.3.2 YEARS CONSIDERED FOR THE STUDY 24
1.4 CURRENCY USED FOR THE STUDY 25
1.5 STAKEHOLDERS 25
1.6 SUMMARY OF CHANGES 25
2 RESEARCH METHODOLOGY 27
2.1 RESEARCH DATA 27
FIGURE 1 RESEARCH DESIGN 27
2.1.1 SECONDARY DATA 28
2.1.1.1 Indicative list of secondary sources 29
2.1.2 PRIMARY DATA 29
FIGURE 2 BREAKDOWN OF PRIMARIES: CARDIAC MARKER TESTING MARKET 30
2.2 MARKET ESTIMATION METHODOLOGY 30
FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 31
2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION 31
2.2.2 END USER-BASED MARKET ESTIMATION 32
FIGURE 4 MARKET SIZE ESTIMATION: CARDIAC MARKER TESTING MARKET 32
2.2.3 PRIMARY RESEARCH VALIDATION 32
2.3 DATA TRIANGULATION 33
FIGURE 5 DATA TRIANGULATION METHODOLOGY 33
2.4 RESEARCH ASSUMPTIONS 34
2.5 RESEARCH LIMITATIONS 34
3 EXECUTIVE SUMMARY 35
FIGURE 6 CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE,
2020 VS. 2025 (USD MILLION) 35
FIGURE 7 CARDIAC MARKER TESTING MARKET, BY END USER,
2020 VS. 2025 (USD MILLION) 36
FIGURE 8 GEOGRAPHICAL SNAPSHOT OF THE CARDIAC MARKER TESTING MARKET 37
4 PREMIUM INSIGHTS 38
4.1 CARDIAC MARKER TESTING MARKET OVERVIEW 38
FIGURE 9 INCREASING INCIDENCE OF CARDIOVASCULAR DISEASES TO DRIVE MARKET GROWTH 38
4.2 CARDIAC MARKER TESTING MARKET SHARE, BY PRODUCT, 2020 VS. 2025 39
FIGURE 10 REAGENTS & KITS SEGMENT WILL CONTINUE TO DOMINATE THE CARDIAC MARKER TESTING MARKET IN 2025 39
4.3 CARDIAC MARKER TESTING MARKET, BY REGION, 2020–2025 39
FIGURE 11 APAC REGION TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD 39
5 MARKET OVERVIEW 40
5.1 INTRODUCTION 40
5.2 MARKET DYNAMICS 40
FIGURE 12 CARDIAC MARKER TESTING MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES 40
5.2.1 DRIVERS 41
5.2.1.1 Growing incidence of cardiovascular diseases 41
5.2.1.2 Rapidly increasing geriatric population and the subsequent increase in the burden of heart diseases worldwide 41
5.2.1.3 Growing funding from public and private organizations for research on cardiac biomarkers 42
5.2.1.4 Ongoing clinical trials for the identification of novel cardiac biomarkers 42
5.2.2 RESTRAINTS 43
5.2.2.1 Technical problems related to sample collection and storage 43
5.2.2.2 Issues related to regulatory and reimbursement systems 43
5.2.3 OPPORTUNITIES 44
5.2.3.1 Point-of-care testing (POCT) with cardiac biomarkers 44
5.2.3.2 Ongoing research on novel cardiac biomarkers for cardiovascular diseases 44
5.2.3.3 Emerging markets to offer high-growth opportunities for market players 45
5.3 COVID-19 IMPACT ON THE CARDIAC MARKER TESTING MARKET 45
5.4 REGULATORY ANALYSIS 46
5.4.1 US 46
TABLE 1 US: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES 46
FIGURE 13 US: REGULATORY PROCESS FOR IVD DEVICES 47
5.4.2 CANADA 48
FIGURE 14 CANADA: REGULATORY PROCESS FOR IVD DEVICES 48
5.4.3 EUROPE 49
TABLE 2 EUROPE: CLASSIFICATION OF IVD DEVICES 49
FIGURE 15 EUROPE: REGULATORY PROCESS FOR IVD DEVICES 50
5.4.4 JAPAN 51
FIGURE 16 JAPAN: REGULATORY PROCESS FOR IVD DEVICES 51
TABLE 3 JAPAN: CLASSIFICATION OF IVD REAGENTS 51
TABLE 4 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 52
5.4.5 CHINA 52
TABLE 5 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 52
5.4.6 INDIA 52
FIGURE 17 INDIA: REGULATORY PROCESS FOR IVD DEVICES 53
5.4.7 RUSSIA 53
TABLE 6 RUSSIA: CLASSIFICATION OF IVD DEVICES 53
5.4.8 MEXICO 54
FIGURE 18 MEXICO: REGULATORY PROCESS FOR IVD DEVICES 54
TABLE 7 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 54
5.4.9 BRAZIL 55
FIGURE 19 BRAZIL: REGULATORY PROCESS FOR IVD DEVICES 55
5.4.10 SOUTH KOREA 55
TABLE 8 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 55
5.5 REIMBURSEMENT SCENARIO 56
TABLE 9 REIMBURSEMENT CODES FOR VARIOUS BIOMARKERS 56
5.6 VALUE CHAIN ANALYSIS 57
FIGURE 20 CARDIAC MARKER TESTING MARKET: VALUE CHAIN ANALYSIS 57
5.7 ECOSYSTEM: PARENT INDUSTRY (IN VITRO DIAGNOSTICS) 57
5.8 SE CASES: IN VITRO DIAGNOSTICS MARKET 58
5.8.1 REVENUE OPPORTUNITIES: IVD ASSAY DEVELOPMENT SERVICES 58
5.8.2 REVENUE OPPORTUNITIES: IVD CONTRACT RESEARCH SERVICES 58
6 CARDIAC MARKER TESTING MARKET, BY PRODUCT 59
6.1 INTRODUCTION 60
TABLE 10 CARDIAC MARKER TESTING MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 60
6.2 REAGENTS & KITS 60
6.2.1 INCREASING NUMBER OF TESTS PERFORMED TO DRIVE THE MARKET GROWTH 60
TABLE 11 CARDIAC MARKER TESTING REAGENTS AND KITS MARKET, BY REGION, 2018–2025 (USD MILLION) 61
TABLE 12 CARDIAC MARKER TESTING REAGENTS AND KITS MARKET, BY BIOMARKER TYPE, 2018–2025 (USD MILLION) 61
6.3 INSTRUMENTS 61
TABLE 13 CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY TECHNIQUE,
2018–2025 (USD MILLION) 62
TABLE 14 CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY BIOMARKER TYPE, 2018–2025 (USD MILLION) 62
TABLE 15 CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY REGION,
2018–2025 (USD MILLION) 63
6.3.1 CHEMILUMINESCENCE 63
6.3.1.1 Chemiluminescence is the most preferred method for the quantification of cardiac biomarkers 63
TABLE 16 CARDIAC MARKER TESTING INSTRUMENTS MARKET FOR CHEMILUMINESCENCE, BY REGION, 2018–2025 (USD MILLION) 64
TABLE 17 CARDIAC MARKER TESTING INSTRUMENTS MARKET FOR CHEMILUMINESCENCE, BY BIOMARKER TYPE, 2018–2025 (USD MILLION) 64
6.3.2 IMMUNOFLUORESCENCE 64
6.3.2.1 Demand for stable and safer reagents to support market growth 64
TABLE 18 CARDIAC MARKER TESTING INSTRUMENTS MARKET FOR IMMUNOFLUORESCENCE, BY REGION, 2018–2025 (USD MILLION) 65
TABLE 19 CARDIAC MARKER TESTING INSTRUMENTS MARKET FOR IMMUNOFLUORESCENCE, BY BIOMARKER TYPE, 2018–2025 (USD MILLION) 65
6.3.3 ELISA 66
6.3.3.1 Ease of use and simplicity of the method are the key advantages associated with ELISA 66
TABLE 20 CARDIAC MARKER TESTING INSTRUMENTS MARKET FOR ELISA, BY REGION, 2018–2025 (USD MILLION) 66
TABLE 21 CARDIAC MARKER TESTING INSTRUMENTS MARKET FOR ELISA,
BY BIOMARKER TYPE, 2018–2025 (USD MILLION) 66
6.3.4 IMMUNOCHROMATOGRAPHY 67
6.3.4.1 Increasing use in point-of-care settings to fuel the adoption of this technique 67
TABLE 22 CARDIAC MARKER TESTING INSTRUMENTS MARKET FOR IMMUNOCHROMATOGRAPHY, BY REGION, 2018–2025 (USD MILLION) 67
TABLE 23 CARDIAC MARKER TESTING INSTRUMENTS MARKET FOR IMMUNOCHROMATOGRAPHY, BY BIOMARKER TYPE,
2018–2025 (USD MILLION) 67
7 CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE 68
7.1 INTRODUCTION 69
TABLE 24 CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE,
2018–2025 (USD MILLION) 69
7.2 TROPONIN I AND T 69
7.2.1 HIGH SENSITIVITY OF THIS BIOMARKER TEST IS SUPPORTING ITS INCREASED ADOPTION IN THE MARKET 69
TABLE 25 CHARACTERISTICS OF TROPONIN CARDIAC MARKERS 69
TABLE 26 CARDIAC MARKER TESTING MARKET FOR TROPONIN I AND T, BY REGION, 2018–2025 (USD MILLION) 70
TABLE 27 CARDIAC MARKER TESTING MARKET FOR TROPONIN I AND T, BY DISEASE, 2018–2025 (USD MILLION) 70
TABLE 28 CARDIAC MARKER TESTING MARKET FOR TROPONIN I AND T, BY END USER, 2018–2025 (USD MILLION) 71
7.3 CK-MB 71
7.3.1 CK-MB IS USEFUL FOR THE DIAGNOSIS OF ACUTE MYOCARDIAL INJURY 71
TABLE 29 CHARACTERISTICS OF CK-MB CARDIAC MARKERS 71
TABLE 30 CARDIAC MARKER TESTING MARKET FOR CK-MB, BY REGION,
2018–2025 (USD MILLION) 72
TABLE 31 CARDIAC MARKER TESTING MARKET FOR CK-MB, BY DISEASE,
2018–2025 (USD MILLION) 72
TABLE 32 CARDIAC MARKER TESTING MARKET FOR CK-MB, BY END USER,
2018–2025 (USD MILLION) 73
7.4 BNP AND NT-PROBNP 73
7.4.1 THE ABILITY OF THIS BIOMARKER TO BE USED WITH OTHER MARKERS IS SUPPORTING MARKET GROWTH 73
TABLE 33 CARDIAC MARKER TESTING MARKET FOR BNP AND NT-PROBNP, BY REGION, 2018–2025 (USD MILLION) 74
TABLE 34 CARDIAC MARKER TESTING MARKET FOR BNP AND NT-PROBNP,
BY DISEASE, 2018–2025 (USD MILLION) 74
TABLE 35 CARDIAC MARKER TESTING MARKET FOR BNP AND NT-PROBNP,
BY END USER, 2018–2025 (USD MILLION) 75
7.5 MYOGLOBIN 75
7.5.1 RAPID INCREASE AND NORMALIZATION ASSOCIATED WITH MYOGLOBIN TO DRIVE MARKET GROWTH 75
TABLE 36 CHARACTERISTICS OF MYOGLOBIN CARDIAC MARKERS 75
TABLE 37 CARDIAC MARKER TESTING MARKET FOR MYOGLOBIN, BY REGION,
2018–2025 (USD MILLION) 76
TABLE 38 CARDIAC MARKER TESTING MARKET FOR MYOGLOBIN, BY DISEASE,
2018–2025 (USD MILLION) 76
TABLE 39 CARDIAC MARKER TESTING MARKET FOR MYOGLOBIN, BY END USER,
2018–2025 (USD MILLION) 76
7.6 HSCRP 77
7.6.1 ABILITY OF HSCRP TESTS TO ACCURATELY MEASURE LOW LEVELS OF CRP WILL SUPPORT MARKET GROWTH 77
TABLE 40 CUT-OFFS FOR CRP USING STANDARDIZED ASSAY 77
TABLE 41 CARDIAC MARKER TESTING MARKET FOR HSCRP, BY REGION,
2018–2025 (USD MILLION) 78
TABLE 42 CARDIAC MARKER TESTING MARKET FOR HSCRP, BY DISEASE,
2018–2025 (USD MILLION) 78
TABLE 43 CARDIAC MARKER TESTING MARKET FOR HSCRP, BY END USER,
2018–2025 (USD MILLION) 79
7.7 OTHER BIOMARKERS 79
TABLE 44 CARDIAC MARKER TESTING MARKET FOR OTHER BIOMARKERS, BY REGION, 2018–2025 (USD MILLION) 80
TABLE 45 CARDIAC MARKER TESTING MARKET FOR OTHER BIOMARKERS, BY DISEASE, 2018–2025 (USD MILLION) 80
TABLE 46 CARDIAC MARKER TESTING MARKET FOR OTHER BIOMARKERS,
BY END USER, 2018–2025 (USD MILLION) 81
8 CARDIAC MARKER TESTING MARKET, BY DISEASE 82
8.1 INTRODUCTION 83
TABLE 47 CARDIAC MARKER TESTING MARKET, BY DISEASE, 2018–2025 (USD MILLION) 83
8.2 MYOCARDIAL INFARCTION 83
8.2.1 AVAILABILITY OF HIGH-SENSITIVITY BIOMARKERS FOR THE DETECTION OF MI TO SUPPORT MARKET GROWTH 83
TABLE 48 CARDIAC MARKER TESTING MARKET FOR MYOCARDIAL INFARCTION,
BY REGION, 2018–2025 (USD MILLION) 84
8.3 CONGESTIVE HEART FAILURE 84
8.3.1 GROWING USE OF MULTI-MARKER TESTING IS DRIVING MARKET GROWTH 84
TABLE 49 CARDIAC MARKER TESTING MARKET FOR CONGESTIVE HEART FAILURE,
BY REGION, 2018–2025 (USD MILLION) 85
8.4 ACUTE CORONARY SYNDROME 85
8.4.1 INCREASING INCIDENCE OF RISK FACTORS ASSOCIATED WITH ACS TO DRIVE THE ADOPTION OF CARDIAC MARKERS 85
TABLE 50 CARDIAC MARKER TESTING MARKET FOR ACUTE CORONARY SYNDROME,
BY REGION, 2018–2025 (USD MILLION) 86
8.5 ATHEROSCLEROSIS 86
8.5.1 HIGH PREVALENCE OF ATHEROSCLEROSIS WILL PROPEL THE ADOPTION OF CARDIAC MARKERS 86
TABLE 51 CARDIAC MARKER TESTING MARKET FOR ATHEROSCLEROSIS, BY REGION, 2018–2025 (USD MILLION) 87
8.6 ISCHEMIA 87
8.6.1 MULTIPLE COMPLICATIONS CAUSED BY ISCHEMIA IS RESULTING IN THE INCREASED ADOPTION OF DIAGNOSTICS TESTS 87
TABLE 52 CARDIAC MARKER TESTING MARKET FOR ISCHEMIA, BY REGION,
2018–2025 (USD MILLION) 88
9 CARDIAC MARKER TESTING MARKET, BY END USER 89
9.1 INTRODUCTION 90
TABLE 53 CARDIAC MARKER TESTING MARKET, BY END USER,
2018–2025 (USD MILLION) 90
9.2 LABORATORY TESTING FACILITIES 90
TABLE 54 CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2018–2025 (USD MILLION) 91
TABLE 55 CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY REGION, 2018–2025 (USD MILLION) 91
9.2.1 HOSPITAL LABORATORIES 91
9.2.1.1 Emergency patient care and early diagnosis associated with in-house labs to drive market growth 91
TABLE 56 CARDIAC MARKER TESTING MARKET FOR HOSPITAL LABORATORIES,
BY REGION, 2018–2025 (USD MILLION) 92
9.2.2 REFERENCE LABORATORIES 92
9.2.2.1 Cost and time savings associated with reference laboratories to support market growth 92
TABLE 57 CARDIAC MARKER TESTING MARKET FOR REFERENCE LABORATORIES,
BY REGION, 2018–2025 (USD MILLION) 92
9.2.3 CONTRACT TESTING LABORATORIES 93
9.2.3.1 Access to a wide range of tests in such settings allows multiple tests to be performed 93
TABLE 58 CARDIAC MARKER TESTING MARKET FOR CONTRACT TESTING LABORATORIES, BY REGION, 2018–2025 (USD MILLION) 93
9.3 ACADEMIC INSTITUTES 93
9.3.1 CONTINUOUS RESEARCH & DEVELOPMENT OF NOVEL BIOMARKERS TO DRIVE MARKET GROWTH 93
TABLE 59 CARDIAC MARKER TESTING MARKET FOR ACADEMIC INSTITUTES,
BY REGION, 2018–2025 (USD MILLION) 94
9.4 POINT-OF-CARE TESTING FACILITIES 94
9.4.1 EARLY DETECTION AND LOWER TURNAROUND TEST TIME WILL DRIVE MARKET GROWTH 94
TABLE 60 CARDIAC MARKER TESTING MARKET FOR POC TESTING FACILITIES,
BY REGION, 2018–2025 (USD MILLION) 95
10 CARDIAC MARKER TESTING MARKET, BY REGION 96
10.1 INTRODUCTION 97
TABLE 61 CARDIAC MARKER TESTING MARKET, BY REGION,
2018-2025 (USD MILLION) 97
10.2 NORTH AMERICA 98
FIGURE 21 NORTH AMERICA: CARDIAC MARKER TESTING MARKET SNAPSHOT 98
TABLE 62 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 99
TABLE 63 NORTH AMERICA: CARDIAC MARKER TESTING MARKET,
BY BIOMARKER TYPE, 2018–2025 (USD MILLION) 99
TABLE 64 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 99
TABLE 65 NORTH AMERICA: CARDIAC MARKER TESTING INSTRUMENTS MARKET,
BY TECHNOLOGY, 2018–2025 (USD MILLION) 100
TABLE 66 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY END USER, 2018–2025 (USD MILLION) 100
10.2.1 US 100
10.2.1.1 Increasing public-private investments for cardiac biomarker research to drive market growth 100
TABLE 67 US: CARDIAC MARKER TESTING MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 101
10.2.2 CANADA 101
10.2.2.1 Increasing government initiatives to support the cardiac marker testing market in Canada 101
TABLE 68 CANADA: CARDIAC MARKER TESTING MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 102
10.3 EUROPE 102
TABLE 69 EUROPE: CARDIAC MARKER TESTING MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 102
TABLE 70 EUROPE: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE,
2018–2025 (USD MILLION) 103
TABLE 71 EUROPE: CARDIAC MARKER TESTING MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 103
TABLE 72 EUROPE: CARDIAC MARKER TESTING INSTRUMENTS MARKET,
BY TECHNOLOGY, 2018–2025 (USD MILLION) 103
TABLE 73 EUROPE: CARDIAC MARKER TESTING MARKET, BY END USER,
2018–2025 (USD MILLION) 104
10.3.1 GERMANY 104
10.3.1.1 Higher healthcare spending to fuel diagnostic testing 104
TABLE 74 GERMANY: CARDIAC MARKER TESTING MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 104
10.3.2 UK 105
10.3.2.1 Increasing number of accredited clinical laboratories to increase the adoption of cardiac marker tests in the country 105
TABLE 75 UK: CARDIAC MARKER TESTING MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 105
10.3.3 FRANCE 105
10.3.3.1 Increasing demand for early disease diagnosis to drive market growth 105
TABLE 76 FRANCE: CARDIAC MARKER TESTING MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 106
10.3.4 ITALY 106
10.3.4.1 Increasing prevalence of chronic and infectious diseases to drive market growth 106
TABLE 77 ITALY: CARDIAC MARKER TESTING MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 106
10.3.5 SPAIN 106
10.3.5.1 Rising geriatric population in the country to support market growth 106
TABLE 78 SPAIN: CARDIAC MARKER TESTING MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 107
10.3.6 REST OF EUROPE (ROE) 107
TABLE 79 REST OF EUROPE: CARDIAC MARKER TESTING MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 107
10.4 ASIA PACIFIC 108
FIGURE 22 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET SNAPSHOT 109
TABLE 80 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 110
TABLE 81 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2018–2025 (USD MILLION) 110
TABLE 82 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 111
TABLE 83 ASIA PACIFIC: CARDIAC MARKER TESTING INSTRUMENTS MARKET,
BY TECHNOLOGY, 2018–2025 (USD MILLION) 111
TABLE 84 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY END USER,
2018–2025 (USD MILLION) 111
10.4.1 JAPAN 112
10.4.1.1 Presence of a well-developed healthcare system to drive market growth in Japan 112
TABLE 85 JAPAN: CARDIAC MARKER TESTING MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 112
10.4.2 CHINA 112
10.4.2.1 Increasing disposable income of the Chinese population to fuel market growth 112
TABLE 86 CHINA: CARDIAC MARKER TESTING MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 113
10.4.3 INDIA 113
10.4.3.1 Presence of a large patient population to fuel the demand for cardiac marker testing in the country 113
TABLE 87 INDIA: CARDIAC MARKER TESTING MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 114
10.4.4 SOUTH KOREA 114
10.4.4.1 Growing number of private hospitals and independent testing laboratories to drive market growth 114
TABLE 88 SOUTH KOREA: CARDIAC MARKER TESTING MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 114
10.4.5 AUSTRALIA 115
10.4.5.1 High healthcare expenditure in the country to support market growth 115
TABLE 89 AUSTRALIA: CARDIAC MARKER TESTING MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 115
10.4.6 REST OF ASIA PACIFIC (ROAPAC) 115
TABLE 90 REST OF ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2018–2025 (USD MILLION) 115
10.5 LATIN AMERICA 116
TABLE 91 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 116
TABLE 92 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2018–2025 (USD MILLION) 117
TABLE 93 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 117
TABLE 94 LATIN AMERICA: CARDIAC MARKER TESTING INSTRUMENTS MARKET,
BY TECHNOLOGY, 2018–2025 (USD MILLION) 117
TABLE 95 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY END USER,
2018–2025 (USD MILLION) 118
10.5.1 BRAZIL 118
10.5.1.1 Rising investments by leading IVD manufacturers in the country to drive market growth 118
TABLE 96 BRAZIL: CARDIAC MARKER TESTING MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 118
10.5.2 MEXICO 119
10.5.2.1 Availability of technologically advanced IVD products in the country to propel market growth 119
TABLE 97 MEXICO: CARDIAC MARKER TESTING MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 119
10.5.3 REST OF LATIN AMERICA 119
TABLE 98 REST OF LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2018–2025 (USD MILLION) 120
10.6 MIDDLE EAST & AFRICA 120
10.6.1 IMPROVING HEALTHCARE INFRASTRUCTURE TO DRIVE MARKET GROWTH 120
TABLE 99 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET,
BY BIOMARKER TYPE, 2018–2025 (USD MILLION) 120
TABLE 100 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2018–2025 (USD MILLION) 121
TABLE 101 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY TECHNOLOGY, 2018–2025 (USD MILLION) 121
TABLE 102 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY END USER, 2018–2025 (USD MILLION) 121

11 COMPETITIVE LANDSCAPE 122
11.1 INTRODUCTION 122
11.2 STRATEGIC OVERVIEW 122
FIGURE 23 KEY DEVELOPMENTS IN THE CARDIAC MARKER TESTING MARKET,
2017- 2020 122
11.3 MARKET SHARE ANALYSIS 123
FIGURE 24 CARDIAC MARKER TESTING MARKET SHARE, BY KEY PLAYER, 2019 123
11.4 COMPETITIVE SCENARIO 124
11.5 KEY MARKET DEVELOPMENTS 125
11.5.1 PRODUCT LAUNCHES AND APPROVALS 125
11.5.2 ACQUISITIONS 125
11.5.3 PARTNERSHIPS, COLLABORATIONS, AND AGREEMENTS 126
11.5.4 EXPANSIONS 126
12 COMPANY EVALUATION MATRIX AND COMPANY PROFILES 127
12.1 COMPANY EVALUATION MATRIX 127
12.1.1 STARS 127
12.1.2 EMERGING LEADERS 127
12.1.3 EMERGING COMPANIES 127
12.1.4 PERVASIVE 128
FIGURE 25 CARDIAC MARKER TESTING MARKET: COMPETITIVE LEADERSHIP MAPPING, 2019 128
12.2 COMPANY PROFILES 129
(Business overview, Products offered, Recent developments, MNM view)*
12.2.1 ABBOTT LABORATORIES 129
FIGURE 26 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2019) 129
12.2.2 BECTON, DICKINSON AND COMPANY 131
FIGURE 27 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2019) 131
12.2.3 BIOMÉRIEUX SA 133
FIGURE 28 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2019) 133
12.2.4 BIO-RAD LABORATORIES, INC. 135
FIGURE 29 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2019) 135
12.2.5 DANAHER CORPORATION 137
FIGURE 30 DANAHER CORPORATION: COMPANY SNAPSHOT (2019) 137
12.2.6 DIASORIN 140
FIGURE 31 DIASORIN: COMPANY SNAPSHOT (2019) 140
12.2.7 F. HOFFMANN-LA ROCHE AG 142
FIGURE 32 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2019) 142
12.2.8 GUANGZHOU WONDFO BIOTECH CO., LTD. 144
12.2.9 LSI MEDIENCE CORPORATION 145
FIGURE 33 MITSUBISHI CHEMICAL HOLDINGS CORPORATION: COMPANY SNAPSHOT (2019) 145
12.2.10 ORTHO CLINICAL DIAGNOSTICS 147
12.2.11 PERKINELMER, INC. 148
FIGURE 34 PERKINELMER: COMPANY SNAPSHOT (2019) 148
12.2.12 RANDOX LABORATORIES 150
12.2.13 SIEMENS HEALTHINEERS AG 152
FIGURE 35 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2019) 152
12.2.14 THERMO FISHER SCIENTIFIC 155
FIGURE 36 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2019) 155
12.2.15 TOSOH CORPORATION 157
FIGURE 37 TOSOH CORPORATION: COMPANY SNAPSHOT (2019) 157
*Business overview, Products offered, Recent developments, MNM view might not be captured in case of unlisted companies.
13 APPENDIX 159
13.1 DISCUSSION GUIDE 159
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 163
13.3 AVAILABLE CUSTOMIZATIONS 165
13.4 RELATED REPORTS 166
13.5 AUTHOR DETAILS 167



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[世界の心臓マーカー検査市場(~2025年):製品別(試薬、機器)、構成要素別(トロポニンI&T、CK-MB、ミオグロビン、BNP、hsCRP)、疾患別(心筋梗塞、うっ血性心不全、アテローム性動脈硬化症)、エンドユーザー別(研究所、PoC、学術)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆